BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic Translational Science Meeting
BCAB Stock | USD 1.44 0.01 0.70% |
About 72 percent of all Bioatla's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Bioatla suggests that quite a large number of traders are confidant. The current market sentiment, together with Bioatla's historical and current headlines, can help investors time the market. In addition, many technical investors use Bioatla stock news signals to limit their universe of possible portfolio assets.
Bioatla |
SAN DIEGO, Dec. 10, 2024 -- BioAtla, Inc. , a global clinical-stage biotechnology company focused on the development of...
Read at globenewswire.com
Bioatla Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Bioatla can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bioatla Fundamental Analysis
We analyze Bioatla's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioatla using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioatla based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Bioatla is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Bioatla Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bioatla stock to make a market-neutral strategy. Peer analysis of Bioatla could also be used in its relative valuation, which is a method of valuing Bioatla by comparing valuation metrics with similar companies.
Peers
Bioatla Related Equities
ACRV | Acrivon Therapeutics, | 3.28 | ||||
PMVP | Pmv Pharmaceuticals | 0.63 | ||||
PASG | Passage Bio | 0.38 | ||||
AVTE | Aerovate Therapeutics | 0.00 | ||||
KYMR | Kymera Therapeutics | 1.49 | ||||
ERAS | Erasca | 1.52 | ||||
ANTX | AN2 Therapeutics | 2.03 | ||||
GLUE | Monte Rosa | 2.05 | ||||
IKNA | Ikena Oncology | 2.35 | ||||
IPSC | Century Therapeutics | 2.40 | ||||
CCCC | C4 Therapeutics | 2.78 | ||||
ADAG | Adagene | 2.84 | ||||
RZLT | Rezolute | 3.23 | ||||
STTK | Shattuck Labs | 3.33 | ||||
NAUT | Nautilus Biotechnology | 3.92 | ||||
OLMA | Olema Pharmaceuticals | 5.95 | ||||
NRIX | Nurix Therapeutics | 6.29 | ||||
FHTX | Foghorn Therapeutics | 6.92 | ||||
DSGN | Design Therapeutics | 11.40 |
Complementary Tools for Bioatla Stock analysis
When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |